142 related articles for article (PubMed ID: 32005270)
1. Repurposing chlorpromazine in the treatment of glioblastoma multiforme: analysis of literature and forthcoming steps.
Abbruzzese C; Matteoni S; Persico M; Villani V; Paggi MG
J Exp Clin Cancer Res; 2020 Jan; 39(1):26. PubMed ID: 32005270
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing for the treatment of glioblastoma multiforme.
Abbruzzese C; Matteoni S; Signore M; Cardone L; Nath K; Glickson JD; Paggi MG
J Exp Clin Cancer Res; 2017 Nov; 36(1):169. PubMed ID: 29179732
[TBL] [Abstract][Full Text] [Related]
3. Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response.
Matteoni S; Matarrese P; Ascione B; Ricci-Vitiani L; Pallini R; Villani V; Pace A; Paggi MG; Abbruzzese C
J Exp Clin Cancer Res; 2021 Nov; 40(1):347. PubMed ID: 34740374
[TBL] [Abstract][Full Text] [Related]
4. Repurposing drugs for glioblastoma: From bench to bedside.
Basso J; Miranda A; Sousa J; Pais A; Vitorino C
Cancer Lett; 2018 Aug; 428():173-183. PubMed ID: 29729291
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation
Matteoni S; Matarrese P; Ascione B; Buccarelli M; Ricci-Vitiani L; Pallini R; Villani V; Pace A; Paggi MG; Abbruzzese C
Front Oncol; 2021; 11():635472. PubMed ID: 33718225
[TBL] [Abstract][Full Text] [Related]
6. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Oliva CR; Zhang W; Langford C; Suto MJ; Griguer CE
Oncotarget; 2017 Jun; 8(23):37568-37583. PubMed ID: 28455961
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
11. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
12. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
13. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
14. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
16. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M
Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
18. [Early postsurgical temozolomide treatment in newly diagnosed bad prognosis glioblastoma patients: Feasibility study].
Chaskis E; Luce S; Goldman S; Sadeghi N; Melot C; De Witte O; Devriendt D; Lefranc F
Bull Cancer; 2018; 105(7-8):664-670. PubMed ID: 29937336
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
